Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT is a research paper published in Health Technology Assessment (2022). On theSindex it has a DataRank of 0.586. It has been cited 12 times, with 12 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.385
From this paper's citation signal
Citation Network Contribution
0.201
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 12 citers.
Health Technology Assessment programme
Grant: 08/56/04
National Health and Medical Research Council (NHMRC)
Grant: 626939
Plasma Exchange and Glucocorticoids in ANCA Associated Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
National Health and Medical Research Council (NHMRC)
Grant: 1086192
Plasma exchange and glucocorticoids in anti-neutrophil cytoplasm antibody associated systemic vasculitis: a randomised controlled trial (PEXIVAS Australia)
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 1R01DA003516-01A1
A CONTROLLED STUDY OF NALTREXONE MAINTENANCE
FDA HHS
Grant: R01 FD003516
FWCI
1.22
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals